Article
Estimation of PfRh5-based vaccine efficacy in asymptomatic Plasmodium falciparum patients from high-endemic areas of Tanzania using genetic and antigenicity variation screening.
Frontiers in immunology - 1 Jan 2024
Jun Hojong, Mazigo Ernest, Lee Wang-Jong, Louis Johnsy Mary, Syahada Jadidan Hada, Fitriana Fadhila, Heo Jin, Kim Yeonkyung, Kwon Boeun, Muh Fauzi, Lu Feng, Ahmed Md Atique, Lee Se Jin, Na Sunghun, Chun Wanjoo, Park Won Sun, Hong Min, Han Joon-Hee, Kwon Tae-Hyung, Lee Soo-Ung, Han Eun-Teak, Todd Jim, Manjurano Alphaxard, Kidima Winifrida, Han Jin-Hee
Abstract excerpt
Background: Plasmodium falciparum is the most lethal malaria parasite. Recent phase 1b vaccine trials using P. falciparum reticulocyte binding protein homolog 5 (PfRh5) demonstrated safety and promising efficacy in preventing merozoite invasion. PfRh5 has emerged as a strong vaccine candidate due to its essential role in merozoite invasion and limited sequence variation. For effective malaria vaccine development,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
